This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Feb 28, 2025
•
12 min read
Vertex Pharmaceuticals & Verve Therapeutics end liver disease gene editing collab, BeiGene's BTK inhibitor surpasses AstraZeneca's BTK inhibitor in quarterly sales, Medigene & EpimAb Biotherapeutics co-developing TCR-guided T cell engagers for solid tumors, big pharma players (Eli Lilly, Bristol Myers Squibb, Sanofi and Roche) defy Trump administration’s DEI stance by affirming commitment to diverse clinical trials, Regeneron abandons accelerated approval ambitions for bispecific odronextamab in B cell lymphoma + 31 more stories
Feb 27, 2025
10 min read
Eli Lilly commits a whopping $27B to build four new US production facilities, Eikon Therapeutics lands a $350.7M Series D to advance engineering + molecular biology driven drug discovery, HBM Alpha Therapeutics licenses CRH antibody therapy to undisclosed partner for up to $395M, AstraZeneca touts positive Ph3 data for camizestrant (estrogen receptor degrader) in certain forms of breast cancer, Idorsia hits dire funding straits as global rights sale of hypertension drug Tryvio falls through + 24 more stories
Feb 26, 2025
Eli Lilly reduces Zepbound vial prices, Regeneron's genetic hearing loss gene therapy improves hearing in 12 pediatric patients, Castle Creek Biosciences $75M royalty financing from Ligand Pharmaceuticals, Takeda & BridGene Biosciences sign $770M small molecule drug discovery/design partnership using IMTAC platform to discovery/design partnership, J&J sues Samsung Bioepis over alleged unlawful Stelara biosimilar sublicensing agreement + 34 more stories
Feb 25, 2025
Pfizer and Summit Therapeutics partner to test ivonescimab with Pfizer's ADCs in solid tumors, Amgen to invest $200 million in new Indian tech center focused on AI and data science for drug development, Hengrui Medicine's positive Ph3 data for CDK4/6 inhibitor + endocrine therapy in breast cancer, Entrada Therapeutics' exon 44 skipping therapy for Duchenne muscular dystrophy cleared FDA clinical hold, FDA declines to expand Invivyd's Pemgarda COVID-19 emergency use authorization + 25 more stories
Feb 24, 2025
11 min read
bluebird bio bought by PE for $29M (down from $10B valuation), FDA declares semaglutide shortage is over (good news for Novo Nordisk, bad news for compounders like Hims & Hers), Gilead's PPAR-delta agonist Livdelzi lands European approval for primary biliary cholangitis, Eli Lilly invest $500M+ into supply of yet-to-be-approved oral obesity pill orforglipron, Pfizer discontinues hemophilia B gene therapy Beqvez globally + 26 more stories
Feb 21, 2025
BridgeBio reports strong initial demand for Attruby (outpacing investor expectations), Genmab's bispecific Epkinly nabs MHLW (Japan) approval for relapsed/refractory follicular lymphoma, EG 427's €27M ($28.4M) Series B to develop herpes virus-based gene therapy for bladder control in spinal injury patients, AstraZeneca acquires FibroGen's China operations for $160M, CDC delays first vaccine advisory committee meeting under new administration + 37 more stories
Feb 20, 2025
Recursion-backed Altitude Labs launches pre-seed fund to help address funding gap caused by NIH cuts, CSPC Pharmaceutical out-licenses ROR1-targeting ADC to Radiance Biopharma for up to $1.2B, Cabaletta Bio's CD19-targeting CAR-T shows promise in lupus + dermatomyositis Ph1/2 trial, Merck & Co. & Epitopea partner to discover hidden tumor antigens, CRISPR gene-editing hopeful Spotlight Therapeutics shutters + 29 more stories
Feb 19, 2025
Gilead declines option to license Arcus Biosciences' kidney cancer hopeful casdatifan, Bavarian Nordic's chikungunya vaccine lands FDA approval for those aged 12 and older, BioArctic scores €10M ($10.4M) milestone payment as Eisai's Leqembi hits €200M ($209M) in sales, Solid Biosciences showcases solid Ph1/2 data for SGT-003 gene therapy in DMD, Latigo Biotherapeutics hopes to jump on the non-opioid pain hype train with a planned $150M raise ($50M raised thus far) + 28 more stories
Feb 18, 2025
13 min read
FDA (and CDC) mass layoffs begin, Allogene Therapeutics’ allogeneic CAR-T delivers “durable response data” in Ph1 trial, Bambusa Therapeutics raises $90M Series A to develop bispecific antibodies for I&I disorders, BMS' Opdualag flops in Ph3 melanoma trial, Kojin Therapeutics cell death ambitions die as biotech ceases operations + 35 more stories
Feb 14, 2025
Vaccine skeptic RFK Jr. sworn in as HHS Secretary, Newleos Therapeutics launches with $94M in funding and four neuropsychiatry drug hopefuls from Roche, Astellas' once-monthly Izervay nabs FDA approval in macular degeneration, Nobel Prize-Winning UW lab develops AI model to create custom enzymes, Aardvark IPO's at lower end of pricing range and shares drop 10% on first trading day + 25 more stories
Feb 13, 2025
Biogen signs $250M royalty agreement to fund litifilimab development and commercialization, Roche's Evrysdi tablets for SMA land FDA approval, AbbVie signs another T-cell engager partnership (this time with Xilio Therapeutics), Astellas shifts investment focus away from "novel" technologies in regenerative medicine, Kaiser Permanente demands stronger adherence to confirmatory trials as part of accelerated approval pathway + 31 more stories
Feb 12, 2025
Novartis to acquire Anthos Therapeutics for up to $3.1B (buying back abelacimab), Pfizer's accidentally releases early their (positive) Ph1 data for mevrometostat + Xtandi in prostate cancer, SpringWorks Therapeutics' Gomekli receives FDA approval for inoperable plexiform neurofibromas in neurofibromatosis type 1 patients, Voyager Therapeutics halts development of ALS gene therapy hopeful due to preclinical off-target effects, FDA hands warning letters to two Chinese API manufacturers over quality control issues + 24 more stories
